Tempest Acquires CAR-T Assets, Expands Pipeline
- Transaction Closure: Tempest Therapeutics has completed an all-stock transaction with Factor Bioscience, acquiring dual-targeting CAR-T assets including TPST-2003, which is set for a biologics license application (BLA) in China by 2027, potentially opening new revenue streams and enhancing market competitiveness.
- Operational Runway Extended: The transaction extends Tempest's operational runway to mid-2027, supporting multiple potential value-generating milestones, with significant clinical advancements expected in the next 12-18 months, thereby boosting investor confidence.
- New CEO Appointment: Dr. Matt Angel has been appointed as the new President and CEO of Tempest, and his leadership is anticipated to drive innovation in cancer therapies, further strengthening the company's strategic direction and leadership.
- Clinical Trial Progress: The Phase 1 trial of TPST-2003 in relapsed/refractory multiple myeloma patients has been completed, with data expected in 2026 and a BLA planned for 2027 in China, laying the groundwork for the company's expansion in global markets.
Trade with 70% Backtested Accuracy
Analyst Views on TPST
About TPST
About the author
Tempest Acquires CAR-T Assets, Expands Pipeline
- Transaction Closure: Tempest Therapeutics has completed an all-stock transaction with Factor Bioscience, acquiring dual-targeting CAR-T assets including TPST-2003, which is set for a biologics license application (BLA) in China by 2027, potentially opening new revenue streams and enhancing market competitiveness.
- Operational Runway Extended: The transaction extends Tempest's operational runway to mid-2027, supporting multiple potential value-generating milestones, with significant clinical advancements expected in the next 12-18 months, thereby boosting investor confidence.
- New CEO Appointment: Dr. Matt Angel has been appointed as the new President and CEO of Tempest, and his leadership is anticipated to drive innovation in cancer therapies, further strengthening the company's strategic direction and leadership.
- Clinical Trial Progress: The Phase 1 trial of TPST-2003 in relapsed/refractory multiple myeloma patients has been completed, with data expected in 2026 and a BLA planned for 2027 in China, laying the groundwork for the company's expansion in global markets.
Tempest Therapeutics Announces Warrant Dividend Distribution Date of January 30, 2026
- Warrant Distribution: Tempest Therapeutics announced a record date of January 30, 2026, for stockholders to receive warrants as a dividend, with distribution expected on February 3, 2026, contingent on closing conditions, aimed at enhancing shareholder value and attracting investor interest.
- Warrant Terms: Stockholders will receive one warrant for each share held, with an exercise price of $18.48 per share, and the warrants will be valid for five years post-distribution, a strategy likely to boost stock price and market confidence.
- Shareholder Approval Requirement: The distribution of warrants requires stockholder approval of Proposal 5, reflecting the company's commitment to shareholder engagement and transparency, which aims to build investor trust.
- Registration Statement Plan: Tempest intends to file a registration statement with the SEC after submitting its 2025 Annual Report to register the common stock underlying the warrants, a move that will support future financing and business expansion, further solidifying its position in the biotechnology sector.
Tempest Therapeutics Closes $4.25 Million Registered Direct Offering
- Successful Financing: Tempest Therapeutics has completed a registered direct offering of 1,172,414 shares at $3.625 per share, raising approximately $4.25 million, which provides essential liquidity to support its clinical development efforts.
- Short-Term Warrants Issued: The company concurrently issued short-term unregistered warrants allowing the purchase of the same number of shares at an exercise price of $3.50, potentially generating an additional $4.1 million if fully exercised, enhancing future financial flexibility.
- Market Compliance: This financing adheres to Nasdaq regulations, ensuring the company's compliance in capital markets, which boosts investor confidence and lays the groundwork for future fundraising efforts.
- Clear Use of Proceeds: The company intends to use the net proceeds primarily for working capital and general corporate purposes, demonstrating its commitment to ongoing operations and R&D investments aimed at advancing its cancer therapeutics to market.
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
Crude Oil Declines More Than 2%; Lowe's Stock Rises Following Q3 Earnings Report
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones down 0.23%, while the NASDAQ and S&P 500 saw slight gains of 0.19% and 0.08%, respectively.
Lowe's Earnings Report: Lowe's Companies, Inc. shares rose over 5% after exceeding profit expectations for Q3, reporting adjusted earnings per share of $3.06, although sales fell slightly short.
Notable Stock Movements: WeShop Holdings saw a dramatic 413% increase following its Nasdaq debut, while Agios Pharmaceuticals and Carver Bancorp experienced significant declines of 50% and 51%, respectively.
Commodity and Economic Updates: Oil prices fell by 2.4% to $59.26, while gold and silver saw slight increases. The U.S. trade deficit narrowed to $59.6 billion in August, with a notable decline in crude oil inventories.
Nasdaq Rises by More Than 100 Points; Target Lowers Earnings Outlook
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite gaining over 100 points, while the Dow fell by 0.20%. The S&P 500 also saw a slight increase of 0.35%.
Target Corporation Earnings Report: Target reported a third-quarter profit that exceeded expectations but fell short on sales, leading to a reduction in its full-year earnings outlook.
Notable Stock Movements: WeShop Holdings saw a significant increase of 148% following its Nasdaq debut, while Freight Technologies surged 77% after launching a new AI platform. Conversely, Inspire Veterinary Partners and Carver Bancorp experienced substantial declines.
Commodity and Economic Updates: Oil prices dropped by 2.3%, while gold and silver saw slight increases. Additionally, U.S. crude oil inventories fell more than expected, and the trade deficit narrowed significantly in August.
Tempest Acquires CAR-T Assets, Expands Pipeline
- Transaction Closure: Tempest Therapeutics has completed an all-stock transaction with Factor Bioscience, acquiring dual-targeting CAR-T assets including TPST-2003, which is set for a biologics license application (BLA) in China by 2027, potentially opening new revenue streams and enhancing market competitiveness.
- Operational Runway Extended: The transaction extends Tempest's operational runway to mid-2027, supporting multiple potential value-generating milestones, with significant clinical advancements expected in the next 12-18 months, thereby boosting investor confidence.
- New CEO Appointment: Dr. Matt Angel has been appointed as the new President and CEO of Tempest, and his leadership is anticipated to drive innovation in cancer therapies, further strengthening the company's strategic direction and leadership.
- Clinical Trial Progress: The Phase 1 trial of TPST-2003 in relapsed/refractory multiple myeloma patients has been completed, with data expected in 2026 and a BLA planned for 2027 in China, laying the groundwork for the company's expansion in global markets.
Tempest Therapeutics Announces Warrant Dividend Distribution Date of January 30, 2026
- Warrant Distribution: Tempest Therapeutics announced a record date of January 30, 2026, for stockholders to receive warrants as a dividend, with distribution expected on February 3, 2026, contingent on closing conditions, aimed at enhancing shareholder value and attracting investor interest.
- Warrant Terms: Stockholders will receive one warrant for each share held, with an exercise price of $18.48 per share, and the warrants will be valid for five years post-distribution, a strategy likely to boost stock price and market confidence.
- Shareholder Approval Requirement: The distribution of warrants requires stockholder approval of Proposal 5, reflecting the company's commitment to shareholder engagement and transparency, which aims to build investor trust.
- Registration Statement Plan: Tempest intends to file a registration statement with the SEC after submitting its 2025 Annual Report to register the common stock underlying the warrants, a move that will support future financing and business expansion, further solidifying its position in the biotechnology sector.
Tempest Therapeutics Closes $4.25 Million Registered Direct Offering
- Successful Financing: Tempest Therapeutics has completed a registered direct offering of 1,172,414 shares at $3.625 per share, raising approximately $4.25 million, which provides essential liquidity to support its clinical development efforts.
- Short-Term Warrants Issued: The company concurrently issued short-term unregistered warrants allowing the purchase of the same number of shares at an exercise price of $3.50, potentially generating an additional $4.1 million if fully exercised, enhancing future financial flexibility.
- Market Compliance: This financing adheres to Nasdaq regulations, ensuring the company's compliance in capital markets, which boosts investor confidence and lays the groundwork for future fundraising efforts.
- Clear Use of Proceeds: The company intends to use the net proceeds primarily for working capital and general corporate purposes, demonstrating its commitment to ongoing operations and R&D investments aimed at advancing its cancer therapeutics to market.
Butterfly Network and Citius Pharma Boost Biotech Activity in After-Hours Trading
Butterfly Network Update: Butterfly Network's shares rose 6.04% after announcing CEO Joseph DeVivo and Interim CFO Megan Carlson will participate in investor meetings at the Evercore Healthcare Conference on December 2, 2025, highlighting their handheld ultrasound technology.
Citius Pharmaceuticals Collaboration: Citius Pharmaceuticals saw a 7.90% increase in shares after announcing a collaboration with Verix to utilize its AI-powered Tovana platform for the U.S. commercialization of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma.
General Market Activity: ProQR Therapeutics, Perrigo Company, and Tempest Therapeutics also experienced share price increases, with Tempest announcing plans to acquire CAR-T programs to enhance its pipeline.
Other Stocks Performance: Iterum Therapeutics and Processa Pharmaceuticals had minor share price movements without any new updates, reflecting varied investor sentiment in the biotech sector.
Crude Oil Declines More Than 2%; Lowe's Stock Rises Following Q3 Earnings Report
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones down 0.23%, while the NASDAQ and S&P 500 saw slight gains of 0.19% and 0.08%, respectively.
Lowe's Earnings Report: Lowe's Companies, Inc. shares rose over 5% after exceeding profit expectations for Q3, reporting adjusted earnings per share of $3.06, although sales fell slightly short.
Notable Stock Movements: WeShop Holdings saw a dramatic 413% increase following its Nasdaq debut, while Agios Pharmaceuticals and Carver Bancorp experienced significant declines of 50% and 51%, respectively.
Commodity and Economic Updates: Oil prices fell by 2.4% to $59.26, while gold and silver saw slight increases. The U.S. trade deficit narrowed to $59.6 billion in August, with a notable decline in crude oil inventories.
Nasdaq Rises by More Than 100 Points; Target Lowers Earnings Outlook
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Nasdaq Composite gaining over 100 points, while the Dow fell by 0.20%. The S&P 500 also saw a slight increase of 0.35%.
Target Corporation Earnings Report: Target reported a third-quarter profit that exceeded expectations but fell short on sales, leading to a reduction in its full-year earnings outlook.
Notable Stock Movements: WeShop Holdings saw a significant increase of 148% following its Nasdaq debut, while Freight Technologies surged 77% after launching a new AI platform. Conversely, Inspire Veterinary Partners and Carver Bancorp experienced substantial declines.
Commodity and Economic Updates: Oil prices dropped by 2.3%, while gold and silver saw slight increases. Additionally, U.S. crude oil inventories fell more than expected, and the trade deficit narrowed significantly in August.
